#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: The topic doesn’t get 🔥 than this. Join our #immunotherapy #lcsm chat tonight in 7 minutes, no matter what type of can…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: One of my oncologists told me yesterday that he gets annoyed that I talk about medical oncology so much. Here it come…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Hope some #lcsm tweeps, peeps, and friends are out there!
Brendon Stiles @BrendonStilesMD
OK...I have 8PM ET. Let's get started. #lcsm
Brendon Stiles @BrendonStilesMD
Welcome to #LCSM Chat! Our topic tonight is “Immunotherapy–the ultimate personalized therapy” #lcsm
Kathleen Skambis @KathleenSkambis
#lcsm
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD Hey Brendon! Thanks for moderating tonight's chat. #lcsm
Faces of Lung Cancer @LungCancerFaces
Deana Hendrickson in Los Angeles here. Excited about tonight's chat! #lcsm
Brendon Stiles @BrendonStilesMD
@n8pennell Never. Although I do like to drop some knowledge. But I know I am annoying. #lcsm
Brendon Stiles @BrendonStilesMD
What is better than allowing your own immune system to fight your cancer? #lcsm
Sara Whitlock @sjwhitlock
Sara here! #lcsm
Brendon Stiles @BrendonStilesMD
More info at https://t.co/Lx9qF406C9 #lcsm
Timothy Craig Allen @TimAllenMDJD
Tim here. #lcsm https://t.co/9dM8uLyawM
Brendon Stiles @BrendonStilesMD
You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
#LCSM @VamsiVelchev reporting on time for #lCSMchat @BrendonStilesMD
Brendon Stiles @BrendonStilesMD
One way to join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm #lcsm
Faces of Lung Cancer @LungCancerFaces
@sjwhitlock Hi Sara! #lcsm
Janet Freeman-Daily @JFreemanDaily
Janet Freeman-Daily in Seattle, enjoying the warmer, drier spring. #lcsm
Peggy Dennis @peggyddennis
#LCSM Happiness is......great scan results! Almost 2 years out. Looking forward to tonights discussion.
Brendon Stiles @BrendonStilesMD
Holy smokes!!!! A lot of my favorites here already! #lcsm
Faces of Lung Cancer @LungCancerFaces
@KathleenSkambis I see you Kathleen! #lcsm
Brendon Stiles @BrendonStilesMD
We'll get started in a few minutes -- please take a moment to introduce yourselves  #lcsm
Brendon Stiles @BrendonStilesMD
I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Not a medical oncologist! #lcsm
Faces of Lung Cancer @LungCancerFaces
@peggyddennis Congrats Peggy! #lcsm
NCI Cancer Stats @NCICancerStats
Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: https://t.co/IlNVjtpQ3z #LCSM https://t.co/m1DtoSh8DP
Brendon Stiles @BrendonStilesMD
Thanks goodness it looks like we have some real experts here -pathologists, oncologists, patients. #lcsm
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD Gotta have a pathologist! #lcsm
Flemming Rasmussen @fgrazz
Listening in from Halifax, NS #lcsm
Janet Freeman-Daily @JFreemanDaily
Welcome Kathleen, Sara, Tim, Vamsi, Peggy and Jeannine! #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@BrendonStilesMD having supercharged engineered T-cells # need CARs and TRUCKs for solid tumors #LCSM
Nathan A. Pennell MD, PhD @n8pennell
Nate Pennell reporting in from Cleveland! #lcsm
Brendon Stiles @BrendonStilesMD
@VamsiVelchev Awesome. Thanks for joining. #lcsm
Dr. David Tom Cooke @DavidCookeMD
Did someone say @lcsmchat ? #LCSM
Timothy Craig Allen @TimAllenMDJD
Howdy, @LungCancerFaces #lcsm https://t.co/tVfBqH1k1I
Paula Ashton @paulalv
#LCSM hi everyone. Paula in hotter than heck Las Vegas
Brendon Stiles @BrendonStilesMD
Power squad all around. #lcsm
John from Alabama @JohnLPender
Checking in. #lcsm
DrSchiaffino @mexicolindo
RT @NCICancerStats: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: htt…
Denise Cutlip @dennycee
Hello from sunny Michigan. #lcsm
Flemming Rasmussen @fgrazz
@BrendonStilesMD I'm none of those...but I still love being here #LCSM
Brendon Stiles @BrendonStilesMD
In this week’s chat we hope to unlock the mystery of immunotherapy: why, who, what, and when? #lcsm
Janet Freeman-Daily @JFreemanDaily
Hi Fleming, Nate and David! #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat
H. Jack West, MD @JackWestMD
Hi, #LCSM chat folks. I'm a Seattle-based med onc with a major focus on lung cancer, looking forward to great discussion of how immunotherapy is changing treatment landscape.
Brendon Stiles @BrendonStilesMD
The pace of new immunotherapy drugs and trials is hard to keep up with for everyone! #lcsm
SWOG Cancer Research Network @SWOG
RT @NCICancerStats: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: htt…
Brendon Stiles @BrendonStilesMD
@fgrazz Gotta have the scientist! #lcsm
Janet Freeman-Daily @JFreemanDaily
Good to see you, Denise and Jack! #lcsm
Timothy Craig Allen @TimAllenMDJD
#PatientsFirst #lcsm https://t.co/ROGJGXL24O
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Brendon Stiles @BrendonStilesMD
Fortunately, we now have many immunotherapy tools for lung cancer! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: What is better than allowing your own immune system to fight your cancer? #lcsm
Nathan A. Pennell MD, PhD @n8pennell
Got some surgical presence tonight! @DavidCookeMD @BrendonStilesMD #lcsm
Brendon Stiles @BrendonStilesMD
Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat   #lcsm
#LCSM Chat @lcsmchat
RT @peggyddennis: #LCSM Happiness is......great scan results! Almost 2 years out. Looking forward to tonights discussion.
Michele @rants_by_egg
#lcsm successfully treated immunotherapy patient here
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves  #lcsm
Brendon Stiles @BrendonStilesMD
If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience  #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Not a medical oncologist! #lc
Dr. David Tom Cooke @DavidCookeMD
RT @n8pennell: Got some surgical presence tonight! @DavidCookeMD @BrendonStilesMD #lcsm
Brendon Stiles @BrendonStilesMD
@rants_by_egg A true expert! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Thanks goodness it looks like we have some real experts here -pathologists, oncologists, patients. #lcsm
Brendon Stiles @BrendonStilesMD
I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow.  #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @rants_by_egg: #lcsm successfully treated immunotherapy patient here
Brendon Stiles @BrendonStilesMD
We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
Joni Fowler @jfowlerpharmd
@BrendonStilesMD Don’t forget the pharmacist! 🙋🏼‍♀️ #lcsm
Timothy Craig Allen @TimAllenMDJD
PD-L1 is my middle name! #lcsm https://t.co/LRtt3olKxV
Janet Freeman-Daily @JFreemanDaily
Welcome to John, Paula, and Michele! #lcsm
Brendon Stiles @BrendonStilesMD
I would like to disclose conflicts – have worked with @merck and @astrazeneca and my wife worked @pfizer and now @ppdCRO I like to think I have no bias. #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO-…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: The pace of new immunotherapy drugs and trials is hard to keep up with for everyone! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Fortunately, we now have many immunotherapy tools for lung cancer! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat   #lc
Janet Freeman-Daily @JFreemanDaily
Hi Joni! I think you're our first pharmacist in #LCSM Chat.
#LCSM Chat @lcsmchat
RT @rants_by_egg: #lcsm successfully treated immunotherapy patient here
Brendon Stiles @BrendonStilesMD
@jfowlerpharmd Critical to have a pharmacist! #lcsm
Fred Gray @fcgiii
Hello #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience  #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
Nathan A. Pennell MD, PhD @n8pennell
Any rad oncs tonight to explain abscopal effect? If not, we’re going with “magic” in the why column! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: PD-L1 is my middle name! #lcsm https://t.co/LRtt3olKxV
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I would like to disclose conflicts – have worked with @merck and @astrazeneca and my wife worked @pfizer and now @ppdC
Brendon Stiles @BrendonStilesMD
T1: How does immunotherapy work and what are the side effects? #lcsm
Janet Freeman-Daily @JFreemanDaily
Hey Fred! Good to see you. @fcgiii #lcsm
Mark Lewis @marklewismd
Hello #LCSM colleagues. I am a GI medical oncologist who is venturing timidly above the diaphragm for once, tempted by all the wonderful -mabs you're discussing. Good evening @lcsmchat
#LCSM Chat @lcsmchat
RT @n8pennell: Any rad oncs tonight to explain abscopal effect? If not, we’re going with “magic” in the why column! #lcsm
Brendon Stiles @BrendonStilesMD
@n8pennell "magic" is a good start. #lcsm
Denise Cutlip @dennycee
@marklewismd Welcome! #lcsm
Nathan A. Pennell MD, PhD @n8pennell
Consulted with AstraZeneca, Lilly, and Regeneron #COI #lcsm
#LCSM Chat @lcsmchat
Welcome! Remember to add #lcsm to your tweets. https://t.co/SVcFtpvjLy
Brendon Stiles @BrendonStilesMD
T1. “Immunotherapy” is a broad topic - includes vaccines, antibodies, & nonspecific therapies that boost immune system #lcsm
#LCSM Chat @lcsmchat
RT @marklewismd: Hello #LCSM colleagues. I am a GI medical oncologist who is venturing timidly above the diaphragm for once, tempted by all…
Brendon Stiles @BrendonStilesMD
Conflicts with pharma for me too in previous tweet #lcsm
Dr. David Tom Cooke @DavidCookeMD
A1 It prevents your own immune system from being turned off by tumor cells, so your immune system can now fight cancers such as #lungcancer #LCSM
Janet Freeman-Daily @JFreemanDaily
@n8pennell Hey Matt Katz (@subatomicdoc) -- we need you tonight to tell us about abscopal effect! #lcsm
Brendon Stiles @BrendonStilesMD
@marklewismd @lcsmchat thanks for joining! #lcsm
KC Dill @kasedill
Checking in from Texas #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. “Immunotherapy” is a broad topic - includes vaccines, antibodies, & nonspecific therapies that boost immune system…
Brendon Stiles @BrendonStilesMD
T1. Immunotherapy generally uses drugs to stimulate your own immune system to work better and attack cancer cells. #lcsm
#LCSM Chat @lcsmchat
RT @n8pennell: Consulted with AstraZeneca, Lilly, and Regeneron #COI #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. “Immunotherapy” is a broad topic - includes vaccines, antibodies, & nonspecific therapies that boost immune system…
#LCSM Chat @lcsmchat
RT @DavidCookeMD: A1 It prevents your own immune system from being turned off by tumor cells, so your immune system can now fight cancers s…
Brendon Stiles @BrendonStilesMD
T1. “Checkpoint inhibitors” are most commonly used in lung cancer. These drugs release the “brakes” from the immune system so it can attack cancer cells. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @n8pennell Hey Matt Katz (@subatomicdoc) -- we need you tonight to tell us about abscopal effect! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Immunotherapy generally uses drugs to stimulate your own immune system to work better and attack cancer cells. #l
Janet Freeman-Daily @JFreemanDaily
@kasedill Hi KC! #lcsm
Gia Sonata @RedGia
#lcsm - late check-in...
Brendon Stiles @BrendonStilesMD
T1. In lung cancer, most of focus has been on the interaction of PD-L1 (from cancer cells) and PD1 made by T cells #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. Immunotherapy generally uses drugs to stimulate your own immune system to work better and attack cancer cells. #l
Cafer BAŞ @brtmnbs
#lcsm
Dr. David Tom Cooke @DavidCookeMD
Think of "checkpoint" as the guard station with the security guard checking your ID and credentials. It's not the point where you realize you are going to win the chess game in another two moves. #LCSM https://t.co/SVdTT4tmdI
Brendon Stiles @BrendonStilesMD
T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm
Janet Freeman-Daily @JFreemanDaily
T1: Some immunotherapies "take the brakes off" the immune system so it can go after certain types of cancer cells. #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@n8pennell The idea of abscopal effect predates IO and is a misnomer in the IO context- we should stop referring to abscopal effect... it is actually “in-vivo immunization” #LCSM
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm
Peggy Dennis @peggyddennis
Peggy from Denver checking in. Don't need yet but Immuno could be next line so very interested in this discussion. #lcsm
Timothy Craig Allen @TimAllenMDJD
This is not chemotherapy or molecular therapy. #lcsm https://t.co/V0jItog67y
Janet Freeman-Daily @JFreemanDaily
@RedGia No problem--welcome! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. “Checkpoint inhibitors” are most commonly used in lung cancer. These drugs release the “brakes” from the immune…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. In lung cancer, most of focus has been on the interaction of PD-L1 (from cancer cells) and PD1 made by T cells #l
Janet Freeman-Daily @JFreemanDaily
@brtmnbs We see you -- welcome! #lcsm
Dr. David Tom Cooke @DavidCookeMD
#LCSM #immunotherapy https://t.co/6SPm8e3Fvz
Krishna Soujanya Gunturu MD @kgunturuMD
Hi, checking in #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @DavidCookeMD: Think of "checkpoint" as the guard station with the security guard checking your ID and credentials. It's not the point…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm
Brendon Stiles @BrendonStilesMD
Here are different types: #lcsm https://t.co/jnehLpt5uy
Nathan A. Pennell MD, PhD @n8pennell
T1: Magic! No, kidding! Immune checkpoints help prevent auto(self)immunity, but Cancer takes advantage of that to escape the immune system since it is technically “you”, no matter how abnormal #lcsm
Nathan A. Pennell MD, PhD @n8pennell
T1 cont: so by blocking these checkpoints (like CTLA-4 and PD-1/PDL1) we stop that from happening and the immune system can attack #lcsm
#LCSM Chat @lcsmchat
RT @DavidCookeMD: Think of "checkpoint" as the guard station with the security guard checking your ID and credentials. It's not the point…
Timothy Craig Allen @TimAllenMDJD
RT @DavidCookeMD: #LCSM #immunotherapy https://t.co/6SPm8e3Fvz
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Here is a good basic review from @freetobreathe and @lung_fund https://t.co/0t2d1e4nIU #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: Some immunotherapies "take the brakes off" the immune system so it can go after certain types of cancer cells. #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @n8pennell The idea of abscopal effect predates IO and is a misnomer in the IO context- we should stop referring to absco…
Janet Freeman-Daily @JFreemanDaily
@marklewismd Good to see you! #lcsm
Brendon Stiles @BrendonStilesMD
T1. Side effects are generally less than with chemotherapy, but are unique and include many “itis” problems. #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: This is not chemotherapy or molecular therapy. #lcsm https://t.co/V0jItog67y
Timothy Craig Allen @TimAllenMDJD
RT @n8pennell: T1: Magic! No, kidding! Immune checkpoints help prevent auto(self)immunity, but Cancer takes advantage of that to escape the…
Timothy Craig Allen @TimAllenMDJD
RT @n8pennell: T1 cont: so by blocking these checkpoints (like CTLA-4 and PD-1/PDL1) we stop that from happening and the immune system can…
Nathan A. Pennell MD, PhD @n8pennell
RT @VamsiVelchev: @n8pennell The idea of abscopal effect predates IO and is a misnomer in the IO context- we should stop referring to absco…
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy
Kathleen Skambis @KathleenSkambis
@VamsiVelchev @n8pennell #lcsm what is IO?
Brendon Stiles @BrendonStilesMD
T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm
Janet Freeman-Daily @JFreemanDaily
@peggyddennis Hi Peggy! #lcsm
Diane @diianeee
Lcsm #lcsm
Brendon Stiles @BrendonStilesMD
T1. As these drugs are more commonly used, doctors need to be more aware of side effects. https://t.co/UcSfnXz1qC #lcsm
Timothy Craig Allen @TimAllenMDJD
And can occasionally be severe. #lcsm https://t.co/29WBTHxTHu
Flemming Rasmussen @fgrazz
RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy
Janet Freeman-Daily @JFreemanDaily
"IO" is a shorthand way to say "immunotherapy" @KathleenSkambis @VamsiVelchev @n8pennell #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm
ALKLungCancerBarbie @VirginiaMByrne
Hi! #lcsm
Dr. David Tom Cooke @DavidCookeMD
Has anyone in the #LCSM community experienced #Immunotherapy side affects, and if so what were/ are they? #LCSM https://t.co/PxzjRlkq0k
Faces of Lung Cancer @LungCancerFaces
@krishna_gunturu Welcome! #lcsm
Michele @rants_by_egg
#lcsm fatigue is my only side effect, easy to push through...but fatigue could be due to age, confounding variable
H. Jack West, MD @JackWestMD
@DavidCookeMD Good analogy: Here a tumor w/high PD-L1 is like a thief who has fake credentials that make immune system more complacent about presuming he should be left alone. Removing credentials & forcing closer look by guard -> better recognition of who belongs & who doesn't. #LCSM
Timothy Craig Allen @TimAllenMDJD
#lcsm https://t.co/KdUH8CEP5D
Vamsi Velcheti, MD @VamsiVelcheti
@BrendonStilesMD Tumors need to have 💡 on to have immune response i.e respond to checkpoint inhibitors unfortunately most don’t have the 💡 on and need more to make them response to immunotherapy #LCSM
Denise Cutlip @dennycee
T1: I’ve had friends develop arthritis, thyroid and pancreas issues shortly after starting pembrolizumab. #lcsm
colleen ziegler @ZieglerColleen
HI, Colleen joining #lcsm
#LCSM Chat @lcsmchat
RT @DavidCookeMD: #LCSM #immunotherapy https://t.co/6SPm8e3Fvz
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: "IO" is a shorthand way to say "immunotherapy" @KathleenSkambis @VamsiVelchev @n8pennell #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy
Sevtap Savas @savaslab
RT @NCICancerStats: Lung #cancer represents 13.5% of all new cancer cases in the United States. Check out our fact sheet for more info: htt…
Nathan A. Pennell MD, PhD @n8pennell
But blocking this protection from self-immune-attack also can allow unintended autoimmune attack on healthy organs, which are all the side effects of checkpoint inhibitors: inflammation of <insert organ name> #lcsm
Janet Freeman-Daily @JFreemanDaily
T1: It's important for patients to know if they are receiving immunotherapy or chemotherapy--side effects are treated differently #lcsm
#LCSM Chat @lcsmchat
RT @n8pennell: T1: Magic! No, kidding! Immune checkpoints help prevent auto(self)immunity, but Cancer takes advantage of that to escape the…
#LCSM Chat @lcsmchat
RT @n8pennell: T1 cont: so by blocking these checkpoints (like CTLA-4 and PD-1/PDL1) we stop that from happening and the immune system can…
Brendon Stiles @BrendonStilesMD
@sjwhitlock Your beautiful thyroid! Blame @n8pennell #lcsm
#LCSM Chat @lcsmchat
RT @n8pennell: But blocking this protection from self-immune-attack also can allow unintended autoimmune attack on healthy organs, which ar…
Dr. David Tom Cooke @DavidCookeMD
And the #lungcancer says: "Papers! Papers?! We don't need no stinking papers!" #LCSM #immunotherapy
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Side effects are generally less than with chemotherapy, but are unique and include many “itis” problems. #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
RT @VamsiVelchev: W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO-…
Dr. David Tom Cooke @DavidCookeMD
RT @TimAllenMDJD: #lcsm https://t.co/KdUH8CEP5D
#LCSM Chat @lcsmchat
RT @JFreemanDaily: "IO" is a shorthand way to say "immunotherapy" @KathleenSkambis @VamsiVelchev @n8pennell #lcsm
Timothy Craig Allen @TimAllenMDJD
#immunotherapy #lcsm https://t.co/xjlNhhTU9L
Denise Cutlip @dennycee
T1: still learning about long term side effects. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @JackWestMD: @DavidCookeMD Good analogy: Here a tumor w/high PD-L1 is like a thief who has fake credentials that make immune system more…
Brendon Stiles @BrendonStilesMD
@VamsiVelchev Great point and topic for research! #lcsm
Peggy Dennis @peggyddennis
RT @BrendonStilesMD: T1. @ASCO just published new adverse event management guidelines in @JCO_ASCO: https://t.co/3wRrRrJu8S #lcsm
Janet Freeman-Daily @JFreemanDaily
@dennycee The trick with immunotherapy is to rev up the immune system enough that it sees the cancer without attacking normal tissue #lcsm
H. Jack West, MD @JackWestMD
@KathleenSkambis @VamsiVelchev @n8pennell IO stands for "immuno-oncology", basically just immunotherapy in the setting of oncology. The most common abbreviation for a long word/concept. #LCSM
Brendon Stiles @BrendonStilesMD
@DavidCookeMD I have had some patients with profound pneumonitis. #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: T1: It's important for patients to know if they are receiving immunotherapy or chemotherapy--side effects are treated di…
Faces of Lung Cancer @LungCancerFaces
@diianeee Hi Diane! #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: @dennycee The trick with immunotherapy is to rev up the immune system enough that it sees the cancer without attacking n…
Brendon Stiles @BrendonStilesMD
@n8pennell @sjwhitlock This is why I annoy the oncologists.... #lcsm
#LCSM Chat @lcsmchat
RT @DavidCookeMD: Has anyone in the #LCSM community experienced #Immunotherapy side affects, and if so what were/ are they? #LCSM https://t…
Janet Freeman-Daily @JFreemanDaily
@diianeee Welcome! #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@BrendonStilesMD Chemotherapy- Radiation- Vaccines- Epigenetic therapy can turn the 💡 in the tumor ON #LCSM
Denise Cutlip @dennycee
@JFreemanDaily @dennycee understood! #lcsm
Dr. David Tom Cooke @DavidCookeMD
That's where the "Itis" side affects come in. Also, people with autoimmune disorders should mostly stay away from #immunotherapy #LCSM https://t.co/DXWl44KAUg
Nathan A. Pennell MD, PhD @n8pennell
Some have also used ICI for immune checkpoint inhibitors #LCSM https://t.co/i5e5D615iq
Timothy Craig Allen @TimAllenMDJD
RT @JackWestMD: @KathleenSkambis @VamsiVelchev @n8pennell IO stands for "immuno-oncology", basically just immunotherapy in the setting of o…
Brendon Stiles @BrendonStilesMD
@DrewMoghanaki in the house. I'm feeling a little abscopal. #lcsm
Nathan A. Pennell MD, PhD @n8pennell
RT @BrendonStilesMD: @n8pennell @sjwhitlock This is why I annoy the oncologists.... #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: @DavidCookeMD I have had some patients with profound pneumonitis. #lcsm
#LCSM Chat @lcsmchat
RT @rants_by_egg: #lcsm fatigue is my only side effect, easy to push through...but fatigue could be due to age, confounding variable
#LCSM Chat @lcsmchat
RT @JackWestMD: @DavidCookeMD Good analogy: Here a tumor w/high PD-L1 is like a thief who has fake credentials that make immune system more…
Michele @rants_by_egg
T1 fatigue is my only side effect, could be due to age, confounding effect! #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @rants_by_egg: T1 fatigue is my only side effect, could be due to age, confounding effect! #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: #lcsm https://t.co/KdUH8CEP5D
Timothy Craig Allen @TimAllenMDJD
RT @DavidCookeMD: That's where the "Itis" side affects come in. Also, people with autoimmune disorders should mostly stay away from #immun
H. Jack West, MD @JackWestMD
@n8pennell or CPI for checkpoint inhibitor #LCSM
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @BrendonStilesMD Tumors need to have 💡 on to have immune response i.e respond to checkpoint inhibitors unfortunately most…
#LCSM Chat @lcsmchat
RT @dennycee: T1: I’ve had friends develop arthritis, thyroid and pancreas issues shortly after starting pembrolizumab. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: It's important for patients to know if they are receiving immunotherapy or chemotherapy--side effects are treated di…
Dr. David Tom Cooke @DavidCookeMD
Quick, fetch me my dictionary. #LCSM https://t.co/WLGOPzzDey
Drew Moghanaki @DrewMoghanaki
Hi team! I’m a Radiation Oncologist who takes care of Veterans with cancer at the Richmond VAMC. Glad to join. #lcsm
Brendon Stiles @BrendonStilesMD
Tough questions coming up. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. As these drugs are more commonly used, doctors need to be more aware of side effects. https://t.co/UcSfnXz1qC #lc
#LCSM Chat @lcsmchat
RT @dennycee: T1: still learning about long term side effects. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @dennycee The trick with immunotherapy is to rev up the immune system enough that it sees the cancer without attacking n…
Denise Cutlip @dennycee
@DrewMoghanaki welcome! #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: @KathleenSkambis @VamsiVelchev @n8pennell IO stands for "immuno-oncology", basically just immunotherapy in the setting of o…
Gia Sonata @RedGia
#lcsm T1. It took a year to figure out that IO damaged my pituitary gland, I'm now on steroids for life due to adrenal insufficiency from it.
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @DavidCookeMD I have had some patients with profound pneumonitis. #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @BrendonStilesMD Chemotherapy- Radiation- Vaccines- Epigenetic therapy can turn the 💡 in the tumor ON #LCSM
#LCSM Chat @lcsmchat
RT @DavidCookeMD: That's where the "Itis" side affects come in. Also, people with autoimmune disorders should mostly stay away from #immun
#LCSM Chat @lcsmchat
RT @n8pennell: Some have also used ICI for immune checkpoint inhibitors #LCSM https://t.co/i5e5D615iq
Brendon Stiles @BrendonStilesMD
@sjwhitlock @n8pennell He is forgiven. #lcsm
#LCSM Chat @lcsmchat
RT @rants_by_egg: T1 fatigue is my only side effect, could be due to age, confounding effect! #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: @n8pennell or CPI for checkpoint inhibitor #LCSM
#LCSM Chat @lcsmchat
RT @DrewMoghanaki: Hi team! I’m a Radiation Oncologist who takes care of Veterans with cancer at the Richmond VAMC. Glad to join. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Important to remember…only 15-30% will benefit. #lcsm
Lung Cancer Sux @LungCancerSux
#lcsm https://t.co/qFHIG4FCGl
#LCSM Chat @lcsmchat
RT @RedGia: #lcsm T1. It took a year to figure out that IO damaged my pituitary gland, I'm now on steroids for life due to adrenal insuffic…
Krishna Soujanya Gunturu MD @kgunturuMD
T1 We are seeing more and more side effects including cardiotoxicty as more people are being treated and followed longer #LCSM https://t.co/ZFMSoJ9YfN
Brendon Stiles @BrendonStilesMD
T2. But remarkably, almost ALL stage IV lung cancer patients should now be considered for immunotherapy! #lcsm
Timothy Craig Allen @TimAllenMDJD
RT @BrendonStilesMD: T2. Important to remember…only 15-30% will benefit. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Immunotherapy has moved into the frontline setting for patients with metastatic cancer. #lcsm
Nathan A. Pennell MD, PhD @n8pennell
Actually most autoimmune disorders still pretty safe to use ICI/CPIs, low % need to stop drug. Especially if relatively mild or dormant #LCSM https://t.co/cCILc91yKk
Janet Freeman-Daily @JFreemanDaily
T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint inhibitors." #lcsm
Dr. David Tom Cooke @DavidCookeMD
A2 Better than Zero. #Immunotherapy #LCSM https://t.co/nQLnWq6TIK
Gia Sonata @RedGia
#lcsm T1: Also, prior to that Costochondritis, lots of pain from inflammation all over, but my chest was severe pain.
Timothy Craig Allen @TimAllenMDJD
#hope #lcsm https://t.co/hgtBtbC3iP
#LCSM Chat @lcsmchat
T2:   Which patients should be considered for immunotherapy and are the drugs different? #lcsm https://t.co/KOyPz6Viyt
Dr. David Tom Cooke @DavidCookeMD
RT @JFreemanDaily: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint…
Dee Sparacio @womenofteal
RT @JFreemanDaily: @btrfly12 @itsthebunk @stales @womenofteal @TheLizArmy @CBlotner_ @MyelomaTeacher #LCSM Chat created a list of vetted on…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Important to remember…only 15-30% will benefit. #lcsm
Matthew Katz, MD @subatomicdoc
@JFreemanDaily @n8pennell Good evening! Sorry to be joining late, I had to pick up kids from rowing team event. Hi folks! #lcsm
#LCSM Chat @lcsmchat
RT @krishna_gunturu: T1 We are seeing more and more side effects including cardiotoxicty as more people are being treated and followed long…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. But remarkably, almost ALL stage IV lung cancer patients should now be considered for immunotherapy! #lcsm
Denise Cutlip @dennycee
T2: learning that tumor burden improved outcomes excited this former smoker. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Immunotherapy has moved into the frontline setting for patients with metastatic cancer. #lcsm
#LCSM Chat @lcsmchat
RT @n8pennell: Actually most autoimmune disorders still pretty safe to use ICI/CPIs, low % need to stop drug. Especially if relatively mild…
Lecia Sequist, MD, MPH @LeciaSequist
Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO agents are fundamentally different than any others. Seems like good clin trial designs and a bit of luck are the differences b/w drugs
Vamsi Velcheti, MD @VamsiVelcheti
@RedGia unfortunately some of the endocrine side effects of IO are irreversible but easy to treat.. key is early detection and close monitoring #LCSM
Timothy Craig Allen @TimAllenMDJD
#lcsm Must leave because #PatientsFirst It was a privilege to participate.
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint…
Brendon Stiles @BrendonStilesMD
T2. For patients with PD-L1 expression >50%, Keytruda monotherapy (@merck) is indicated for both adeno and squamous #lcsm
#LCSM Chat @lcsmchat
RT @DavidCookeMD: A2 Better than Zero. #Immunotherapy #LCSM https://t.co/nQLnWq6TIK
#LCSM Chat @lcsmchat
RT @RedGia: #lcsm T1: Also, prior to that Costochondritis, lots of pain from inflammation all over, but my chest was severe pain.
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: #hope #lcsm https://t.co/hgtBtbC3iP
Dr. David Tom Cooke @DavidCookeMD
A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM
#LCSM Chat @lcsmchat
RT @dennycee: T2: learning that tumor burden improved outcomes excited this former smoker. #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO age…
Brendon Stiles @BrendonStilesMD
T2. Keytruda more than doubled overall survival compared to chemo! KEYNOTE-024 #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @RedGia unfortunately some of the endocrine side effects of IO are irreversible but easy to treat.. key is early detectio…
Janet Freeman-Daily @JFreemanDaily
Hi @leciasequist! Good to see you. #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @n8pennell: Actually most autoimmune disorders still pretty safe to use ICI/CPIs, low % need to stop drug. Especially if relatively mild…
Flemming Rasmussen @fgrazz
RT @BrendonStilesMD: T2. Important to remember…only 15-30% will benefit. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. For patients with PD-L1 expression >50%, Keytruda monotherapy (@merck) is indicated for both adeno and squamous #…
#LCSM Chat @lcsmchat
RT @DavidCookeMD: A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM
Liz Highleyman @LizCancerHealth
@BrendonStilesMD But docs & nurses have rapidly gotten better at promptly recognizing & managing them #lcsm
Nathan A. Pennell MD, PhD @n8pennell
T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in very very ill patients who might benefit from hospice for example #lcsm
Brendon Stiles @BrendonStilesMD
T2. Keytruda can also be used with chemotherapy for patients with PD-L1 expression less than 50% #lcsm
Brendon Stiles @BrendonStilesMD
@LeciaSequist @MGHCancerCenter Thanks for joining! #lcsm
Sara Whitlock @sjwhitlock
T2:But is it true that people with a specific driver are less likely to benefit? #LCSM
Matthew Katz, MD @subatomicdoc
@JFreemanDaily @n8pennell Concept of the abscopal effect is that radiation treatment to one part of the body can contribute to a tumor response somewhere else in the body. Ab-scopal = out of the 'scope' of the radiation field #lcsm #radonc
Janet Freeman-Daily @JFreemanDaily
T2: Most #lungcancer patients whose cancers have driving mutations (EGFR, ALK, ROS1, BRAF, etc.) should NOT have IO as first treatment #lcsm
Brendon Stiles @BrendonStilesMD
T2. Opdivo (@bmsnews – Checkmate-017) and Tecentriq (@genentech - OAK) can be used if you have progressed after chemotherapy. So can Keytruda. #lcsm
Faces of Lung Cancer @LungCancerFaces
@sjwhitlock No you don't! Just remember to add #lcsm to your tweets.
Matthew Katz, MD @subatomicdoc
RT @JFreemanDaily: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint…
Brendon Stiles @BrendonStilesMD
@sjwhitlock Hey! That is next question! #lcsm
Matthew Katz, MD @subatomicdoc
RT @n8pennell: T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in v…
Nathan A. Pennell MD, PhD @n8pennell
T2: Also focus of most trials today to increase the % of pts who benefit, and so far lost of promise! #lcsm
Brendon Stiles @BrendonStilesMD
T2. Opdivo and Keytruda are PD1 inhibitors, while Tecentriq and Imfinzi are PD-L1 inhibitors. #lcsm
H. Jack West, MD @JackWestMD
T2) Most pts are candidates for IO, mostly just Q of when. Not good for pts w/major auto-immune dzs. Otherwise, evidence now supports giving alone as 1st Rx if PD-L1 high or poss low range, or w/chemo for most others except pts w/driver mut'n like EGFR, ALK, etc.-> later. #LCSM
Lecia Sequist, MD, MPH @LeciaSequist
@sjwhitlock Hi @sjwhitlock! This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different story. #LCSM
#LCSM Chat @lcsmchat
#lcsm https://t.co/Y98uf36Cx8
Brendon Stiles @BrendonStilesMD
T2. It is still not clear which patients respond best. PD-L1 expression is commonly used but is not perfect for predicting response. #lcsm
Denise Cutlip @dennycee
T2: some patients fear mentioning side effects- fear of losing IO treatment. #lcsm
Matthew Katz, MD @subatomicdoc
@LeciaSequist @MGHCancerCenter Good evening Lecia! #lcsm
Norman Eng @NoRmiE55
@DavidCookeMD After my dad’s first keytruda treatment a few weeks ago he had been bed ridden - says it feels like his neck snapped and can’t sit up for long periods of time #LCSM
Kathleen Skambis @KathleenSkambis
RT @JFreemanDaily: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint…
Matthew Katz, MD @subatomicdoc
@DrewMoghanaki Hi Drew! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Keytruda more than doubled overall survival compared to chemo! KEYNOTE-024 #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: @sjwhitlock Hi @sjwhitlock! This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different…
#LCSM Chat @lcsmchat
RT @LizCancerHealth: @BrendonStilesMD But docs & nurses have rapidly gotten better at promptly recognizing & managing them #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @dennycee: T2: some patients fear mentioning side effects- fear of losing IO treatment. #lcsm
Liz Highleyman @LizCancerHealth
@LeciaSequist @MGHCancerCenter The CTLA-4 & PD-1/PD-L1 classes differ from each other, but within a class it seems like not so much. #lcsm
Brendon Stiles @BrendonStilesMD
T2. “Tumor mutation burden” may also predict response – how many total mutations does your tumor have (requires special sequencing). #lcsm
Kathleen Skambis @KathleenSkambis
RT @TimAllenMDJD: #hope #lcsm https://t.co/hgtBtbC3iP
#LCSM Chat @lcsmchat
RT @n8pennell: T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in v…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Keytruda can also be used with chemotherapy for patients with PD-L1 expression less than 50% #lcsm
#LCSM Chat @lcsmchat
RT @sjwhitlock: T2:But is it true that people with a specific driver are less likely to benefit? #LCSM
#LCSM Chat @lcsmchat
RT @subatomicdoc: @JFreemanDaily @n8pennell Concept of the abscopal effect is that radiation treatment to one part of the body can contribu…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T2: Most #lungcancer patients whose cancers have driving mutations (EGFR, ALK, ROS1, BRAF, etc.) should NOT have IO as f…
Vamsi Velcheti, MD @VamsiVelcheti
@DavidCookeMD neoadjuvant trials are critical not only to improve long term outcomes but great opportunity for understanding MOA of the IO drugs and biomarker discovery #LCSM @BrendonStilesMD
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Opdivo (@bmsnews – Checkmate-017) and Tecentriq (@genentech - OAK) can be used if you have progressed after chemo…
Krishna Soujanya Gunturu MD @kgunturuMD
T2. There are different FDA approved immunotherapy agents. Like pembrolozimab is approved if PD expression is above 50% in first line setting. Durvalumab is approved after chemo radiation for stage III who can’t undergo surgery. #lcsm
#LCSM Chat @lcsmchat
RT @n8pennell: T2: Also focus of most trials today to increase the % of pts who benefit, and so far lost of promise! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Opdivo and Keytruda are PD1 inhibitors, while Tecentriq and Imfinzi are PD-L1 inhibitors. #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: T2) Most pts are candidates for IO, mostly just Q of when. Not good for pts w/major auto-immune dzs. Otherwise, evidence no…
Brendon Stiles @BrendonStilesMD
T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P
Mark Lewis @marklewismd
See also the great @Bob_Wachter article in the @nytimes on precisely this issue: https://t.co/DtKYanrDHs #lcsm https://t.co/tMnbwI5OA4
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. It is still not clear which patients respond best. PD-L1 expression is commonly used but is not perfect for pred…
#LCSM Chat @lcsmchat
RT @dennycee: T2: some patients fear mentioning side effects- fear of losing IO treatment. #lcsm
#LCSM Chat @lcsmchat
RT @NoRmiE55: @DavidCookeMD After my dad’s first keytruda treatment a few weeks ago he had been bed ridden - says it feels like his neck sn…
Peggy Dennis @peggyddennis
@BrendonStilesMD Mine is 4....was initially told that immuno might not be a great option. Changing tunes? #lcsm
#LCSM Chat @lcsmchat
RT @LizCancerHealth: @LeciaSequist @MGHCancerCenter The CTLA-4 & PD-1/PD-L1 classes differ from each other, but within a class it seems lik…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. “Tumor mutation burden” may also predict response – how many total mutations does your tumor have (requires speci…
Brendon Stiles @BrendonStilesMD
@VamsiVelchev @DavidCookeMD Will get to this in a bit- totally agree! #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @DavidCookeMD neoadjuvant trials are critical not only to improve long term outcomes but great opportunity for understand…
Kathleen Skambis @KathleenSkambis
RT @LeciaSequist: Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO age…
#LCSM Chat @lcsmchat
RT @krishna_gunturu: T2. There are different FDA approved immunotherapy agents. Like pembrolozimab is approved if PD expression is above 50…
Lecia Sequist, MD, MPH @LeciaSequist
Big logistical hurdle is that there is not yet an agreed upon standard for measuring TMB. #LCSM https://t.co/5L9qh2LJsJ
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P
Denise Cutlip @dennycee
So much great info already tonight! #lcsm
#LCSM Chat @lcsmchat
RT @marklewismd: See also the great @Bob_Wachter article in the @nytimes on precisely this issue: https://t.co/DtKYanrDHs #lcsm https://t.c…
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P
H. Jack West, MD @JackWestMD
T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR mut'n & also high PD-L1 was stopped early due to vy poor pt outcomes. Conclusion: BAD IDEA! Targeted therapy vs. EGFR should come first. #LCSM
Dee Sparacio @womenofteal
RT @JFreemanDaily: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint…
Dee Sparacio @womenofteal
RT @JackWestMD: T2) Most pts are candidates for IO, mostly just Q of when. Not good for pts w/major auto-immune dzs. Otherwise, evidence no…
colleen ziegler @ZieglerColleen
RT @BrendonStilesMD: T2. Here is a great up-to-date “ranking” from @Tony_Calles #lcsm https://t.co/9skDtLAi1P
Dr. David Tom Cooke @DavidCookeMD
RT @dennycee: So much great info already tonight! #lcsm
Kathleen Skambis @KathleenSkambis
RT @DavidCookeMD: A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM
Brendon Stiles @BrendonStilesMD
@LeciaSequist Will be challenging to implement clinically. #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
Yes! I should clarify. I meant differences between PD1/PDL1 drugs ! thanks #LCSM https://t.co/wM7StivQ7G
Krishna Soujanya Gunturu MD @kgunturuMD
T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co/TtMs26WfCs
Janet Freeman-Daily @JFreemanDaily
per @LeciaSequist: This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different story. (in response to @sjwhitlock "Is it true that people with a specific driver are less likely to benefit?") #LCSM
Dr. David Tom Cooke @DavidCookeMD
RT @VamsiVelchev: @DavidCookeMD neoadjuvant trials are critical not only to improve long term outcomes but great opportunity for understand…
Mark B, WFI, In SD @MomsOopsBaby
RT @BrendonStilesMD: T2. It is still not clear which patients respond best. PD-L1 expression is commonly used but is not perfect for pred…
Matthew Katz, MD @subatomicdoc
@marklewismd @JFreemanDaily @n8pennell No. Although arguably Dr. Abscopal's like Elijah at Passover. You have to leave the room, open the door to let in an invisible man. When you come back, the wine is gone #lcsm
Brendon Stiles @BrendonStilesMD
T3 coming up. #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR…
#LCSM Chat @lcsmchat
RT @LeciaSequist: Big logistical hurdle is that there is not yet an agreed upon standard for measuring TMB. #LCSM https://t.co/5L9qh2LJsJ
#LCSM Chat @lcsmchat
RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR…
Dr. David Tom Cooke @DavidCookeMD
RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR…
Brendon Stiles @BrendonStilesMD
T3:   Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@sjwhitlock T2: Still a lot of work needed to improve IO options for pts w/ driver mutations- Some early suggestions that chemo-bevacizumab-IO combinations may be beneficial- need to be confirmed in larger trials #LCSM
Brendon Stiles @BrendonStilesMD
T3. This is a challenging question. Because they have other good drugs available, these patients have been excluded from many trials. #lcsm
Dee Sparacio @womenofteal
RT @subatomicdoc: @JFreemanDaily @n8pennell Concept of the abscopal effect is that radiation treatment to one part of the body can contribu…
#LCSM Chat @lcsmchat
RT @LeciaSequist: Yes! I should clarify. I meant differences between PD1/PDL1 drugs ! thanks #LCSM https://t.co/wM7StivQ7G
Nathan A. Pennell MD, PhD @n8pennell
RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR…
#LCSM Chat @lcsmchat
RT @krishna_gunturu: T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co…
Michele @rants_by_egg
T2 OpD wasn't supposed to work for me. Was part of initial prep to receive t-cells. Surprise! T-cells back in deep freeze for 2nd line of defense. Staying w/ OpD. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: per @LeciaSequist: This is (unfortunately) clearly true for single agent IO. Combo with chemo may be a different story.…
Brendon Stiles @BrendonStilesMD
T3. Evidence suggests that they may not respond as well to immunotherapy. #lcsm
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: T3:   Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm
#LCSM Chat @lcsmchat
RT @subatomicdoc: @marklewismd @JFreemanDaily @n8pennell No. Although arguably Dr. Abscopal's like Elijah at Passover. You have to leave th…
MiVQ @MichRadioactiva
RT @JAMAOnc: What is the association between ERBB family mutations and outcomes of patients with lung squamous cell #carcinoma who received…
Paula Ashton @paulalv
RT @krishna_gunturu: T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co…
Brendon Stiles @BrendonStilesMD
T3. EGFR/ALK+ patients had no benefit in CheckMate 057, KEYNOTE-10, OAK, or PACIFIC trials. #lcsm
Diane @diianeee
T3: I talked with my onc today about IO as an option for my egfr LC and she seemed to hinknit is promising sooner than later. #lcsm
Peggy Dennis @peggyddennis
T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM
Cafer BAŞ @brtmnbs
@krishna_gunturu T1: Are the practical dose of pembro and the dose in the clinical trial (2mg/kg I suppose) different? May the severe or long term side effects be because of this? #lcsm
#LCSM Chat @lcsmchat
@subatomicdoc @marklewismd @JFreemanDaily @n8pennell My daughter, the Cantor, will appreciate this. -Deana #lcsm
Dee Sparacio @womenofteal
@subatomicdoc @JFreemanDaily @n8pennell I had never heard that term before. Thanks for explaining. Could you see that in endometrial cancer ? #lcsm #radonc
Gia Sonata @RedGia
@VamsiVelchev It's that early detection that needs more emphasis IMO. #lcsm
Matthew Katz, MD @subatomicdoc
@marklewismd @JFreemanDaily @n8pennell Both fit with abscopal effect. Great stories, but still lacking robust evidence. #lcsm
Brendon Stiles @BrendonStilesMD
T3. Fortunately, there are lots of ongoing trials! https://t.co/JY4yyLgBbt #lcsm
Liz Highleyman @LizCancerHealth
@JackWestMD Is there a reason checkpoint inhibitors don't work well for 1st line treatment -- or is the issue that targeted therapies work better at that point so try them first? #lcsm
Janet Freeman-Daily @JFreemanDaily
Yes, but for most patients with activating mutations, immunotherapy should wait until targeted therapy and then chemo have been tried. #LCSM https://t.co/Ilz4ivqFvm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3:   Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm
Brendon Stiles @BrendonStilesMD
T3. It may be that immunotherapy may work in these patients in combination with other therapies – radiation, antiangiogenic, etc. #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@BrendonStilesMD patients with driver mutations especially EGFR, ALK, ROS should not be treated with IO upfront... IO only an option after or with chemotherapy #LCSM
Brendon Stiles @BrendonStilesMD
How about that shout out to #radonc???? #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhausting possible targeted options is the best lead we have currently though #LCSM https://t.co/6sAkFTfisX
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @sjwhitlock T2: Still a lot of work needed to improve IO options for pts w/ driver mutations- Some early suggestions that…
H. Jack West, MD @JackWestMD
T3) As noted in prior tweet, IO agents should NOT be initial Rx for pts w/driver mutns. Most evidence shows marginal benefit at best, at least given as single agents -> wouldn't say never, but low priority. Some data now supports giving w/chemo (+/- Avastin) may be bettter. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. This is a challenging question. Because they have other good drugs available, these patients have been excluded…
Saman Maleki, PhD @SMImmunology
@sjwhitlock For anti-PD1 drugs to work, tumor-recognizing T cells need to already exist. Pts with driver mutations tend to have less of those T cells in their tumors. That's why single anti-PD1 drugs don't work as well in these pts #LCSM
#LCSM Chat @lcsmchat
RT @rants_by_egg: T2 OpD wasn't supposed to work for me. Was part of initial prep to receive t-cells. Surprise! T-cells back in deep freeze…
Janet Freeman-Daily @JFreemanDaily
This deserves an #LCSM, Nate https://t.co/FGQr2bkbMJ
Brendon Stiles @BrendonStilesMD
Here are some trials. #lcsm https://t.co/IKe92tp5gX
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Evidence suggests that they may not respond as well to immunotherapy. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. EGFR/ALK+ patients had no benefit in CheckMate 057, KEYNOTE-10, OAK, or PACIFIC trials. #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX
#LCSM Chat @lcsmchat
RT @diianeee: T3: I talked with my onc today about IO as an option for my egfr LC and she seemed to hinknit is promising sooner than later.…
#LCSM Chat @lcsmchat
RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM
#LCSM Chat @lcsmchat
RT @brtmnbs: @krishna_gunturu T1: Are the practical dose of pembro and the dose in the clinical trial (2mg/kg I suppose) different? May the…
Dee Sparacio @womenofteal
Just dropping in since I am usually not home on Thurs nights. Dee #ovca survivor and #gyncsm moderator #lcsm
colleen ziegler @ZieglerColleen
RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX
#LCSM Chat @lcsmchat
RT @womenofteal: @subatomicdoc @JFreemanDaily @n8pennell I had never heard that term before. Thanks for explaining. Could you see that in e…
Vamsi Velcheti, MD @VamsiVelcheti
@RedGia with these drugs now more widely used.. oncologists are getting more familiar with these unique side effects.. but still more education needed #LCSM
Denise Cutlip @dennycee
Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM
Liz Highleyman @LizCancerHealth
RT @LeciaSequist: I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhaust…
Brendon Stiles @BrendonStilesMD
@sjwhitlock This is always a challenge. People don't opt for trials until disease is too far gone. We as doctors need to do better managing/explaining. #lcsm
Matthew Katz, MD @subatomicdoc
@womenofteal @JFreemanDaily @n8pennell Potentially. Currently, the hope is that radiation can be used to induce cancer cells to express antigens (or molecular 'red flags') that make cancer cells more identifiable by the immune system, and hypothetically making immunotherapy more effective. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Fortunately, there are lots of ongoing trials! https://t.co/JY4yyLgBbt #lcsm
#LCSM Chat @lcsmchat
RT @LizCancerHealth: @JackWestMD Is there a reason checkpoint inhibitors don't work well for 1st line treatment -- or is the issue that tar…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Yes, but for most patients with activating mutations, immunotherapy should wait until targeted therapy and then chemo ha…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. It may be that immunotherapy may work in these patients in combination with other therapies – radiation, antiangi…
Matthew Katz, MD @subatomicdoc
RT @dennycee: Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @BrendonStilesMD patients with driver mutations especially EGFR, ALK, ROS should not be treated with IO upfront... IO onl…
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX
H. Jack West, MD @JackWestMD
@LizCancerHealth This is only for pts w/EGFR mut'n, not generally. For patients who don't have a driver mutation like EGFR, ALK, etc., latest evidence supports single agent pembrolizumab (Keytruda) for some (esp those w/high PD-L1, +/- those w/lower), or w/chemo combination for most others. #LCSM
Denise Cutlip @dennycee
@womenofteal welcome #lcsm
Dee Sparacio @womenofteal
@JFreemanDaily LOL #lcsm
Kathleen Skambis @KathleenSkambis
RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR…
#LCSM Chat @lcsmchat
RT @LeciaSequist: I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhaust…
Matthew Katz, MD @subatomicdoc
RT @JFreemanDaily: This deserves an #LCSM, Nate https://t.co/FGQr2bkbMJ
#LCSM Chat @lcsmchat
RT @JackWestMD: T3) As noted in prior tweet, IO agents should NOT be initial Rx for pts w/driver mutns. Most evidence shows marginal benefi…
#LCSM Chat @lcsmchat
RT @SMImmunology: @sjwhitlock For anti-PD1 drugs to work, tumor-recognizing T cells need to already exist. Pts with driver mutations tend t…
Saman Maleki, PhD @SMImmunology
Hi #LCSM. I am a tumor immunologist from @SchulichMedDent happy to join the chat and answer immunology questions about #immunotherapy
#LCSM Chat @lcsmchat
RT @JFreemanDaily: This deserves an #LCSM, Nate https://t.co/FGQr2bkbMJ
Brendon Stiles @BrendonStilesMD
T3. Someone tell us about abscopal and antiangiogenic combo! #lcsm
Kathleen Skambis @KathleenSkambis
RT @krishna_gunturu: T2 Exactly @JFreemanDaily. People with mutations should go on oral therapy( targeted therapy) first #lcsm https://t.co…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @RedGia with these drugs now more widely used.. oncologists are getting more familiar with these unique side effects.. bu…
Dee Sparacio @womenofteal
RT @SMImmunology: @sjwhitlock For anti-PD1 drugs to work, tumor-recognizing T cells need to already exist. Pts with driver mutations tend t…
#LCSM Chat @lcsmchat
RT @dennycee: Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM
Brendon Stiles @BrendonStilesMD
@SMImmunology @SchulichMedDent Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @sjwhitlock This is always a challenge. People don't opt for trials until disease is too far gone. We as doctors nee…
#LCSM Chat @lcsmchat
RT @subatomicdoc: @womenofteal @JFreemanDaily @n8pennell Potentially. Currently, the hope is that radiation can be used to induce cancer ce…
#LCSM Chat @lcsmchat
RT @JackWestMD: @LizCancerHealth This is only for pts w/EGFR mut'n, not generally. For patients who don't have a driver mutation like EGFR,…
Paula Ashton @paulalv
RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX
Cafer BAŞ @brtmnbs
@JackWestMD What about pts with mutations but high PD-L1 as well? #lcsm
#LCSM Chat @lcsmchat
RT @SMImmunology: Hi #LCSM. I am a tumor immunologist from @SchulichMedDent happy to join the chat and answer immunology questions about #i
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Someone tell us about abscopal and antiangiogenic combo! #lcsm
H. Jack West, MD @JackWestMD
RT @JFreemanDaily: Yes, but for most patients with activating mutations, immunotherapy should wait until targeted therapy and then chemo ha…
Brendon Stiles @BrendonStilesMD
T3. Had a patient w/ BRAF mutation ask about immunotherapy. Seems like some data in melanoma. Any thoughts for lung? #lcsm
Nathan A. Pennell MD, PhD @n8pennell
@brtmnbs @JackWestMD This was specifically tested in EGFR mutant patients and they don’t respond to single agent CPIs even with high PDL1 #lcsm
#LCSM Chat @lcsmchat
RT @brtmnbs: @JackWestMD What about pts with mutations but high PD-L1 as well? #lcsm
Anita Figueras @scifiknitter
T3 Anita chiming in. EGFR patients are getting the Pembro & chemo triplet as treatment after TKIs are exhausted. #LCSM
#LCSM Chat @lcsmchat
RT @n8pennell: @brtmnbs @JackWestMD This was specifically tested in EGFR mutant patients and they don’t respond to single agent CPIs even w…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Had a patient w/ BRAF mutation ask about immunotherapy. Seems like some data in melanoma. Any thoughts for lung…
Krishna Soujanya Gunturu MD @kgunturuMD
T1 not 100% sure if the dose is the cause for toxicity as nivolumab dose was also different than initial trials. Mechanism is activating the immune system and taking the breaks away. We don’t have any evidence to think that dose is correlated with toxicity unlike chemo. #LCSM https://t.co/COwVeH7NSO
Kathleen Skambis @KathleenSkambis
RT @LeciaSequist: I sincerely hope there will be. I just don't think we have been smart enough to uncover it yet. Chemo + CPI after exhaust…
Denise Cutlip @dennycee
@scifiknitter Hi Anita! #lcsm
Dee Sparacio @womenofteal
@subatomicdoc @JFreemanDaily @n8pennell Interesting. #lcsm
Alex Spira, M.D. @AlexSpiraMDPhD
RT @LeciaSequist: Hi #LCSM! I'm a medical oncologist in Boston @MGHCancerCenter T2: I have not seen convincing data that any of the IO age…
Tong Yin @TongYin_MD
RT @ivybelkins: As a stage IV lung cancer patient, I’ve been on targeted therapy for almost 5 years and it’s certainly been a game-changer…
Mark Lewis @marklewismd
A3. GI here. The lesson from brat-mutant colon cancer has been that you actually drive resistance in CRC by only using an inhibitor like vemurafenib. Have to also block EGFR e.g. S1404 (breaking my own rules of cross-trial and cross-tumor comparison!) #lcsm https://t.co/x7JD6P3B3K
Brendon Stiles @BrendonStilesMD
@brtmnbs @JackWestMD I think data shows, IO still no good. #lcsm
Nathan A. Pennell MD, PhD @n8pennell
@BrendonStilesMD BRAF patient seem to be the one mutant lung cancer population that has a similar response rate to non-mutant Lung Cancer, possibly because more common in smokers so more mutations #lcsm
Francie Pucharich @fpucharich
#LCSM
Janet Freeman-Daily @JFreemanDaily
We don't know. #lungcancer patients who have activating mutations usually don't respond to first-line immunotherapy even if they test high for PD-L1. TMB is too new for us to have that data. #LCSM https://t.co/Ptu1zIwKUZ
Peggy Dennis @peggyddennis
@BrendonStilesMD Can't speak to abscopal positively but Docetaxel/Ramucirumab (anti-angiogenic) has kept me stable for a year now. #lcsm
#LCSM Chat @lcsmchat
RT @krishna_gunturu: T1 not 100% sure if the dose is the cause for toxicity as nivolumab dose was also different than initial trials. Mech…
Kathleen Skambis @KathleenSkambis
RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX
#LCSM Chat @lcsmchat
RT @marklewismd: A3. GI here. The lesson from brat-mutant colon cancer has been that you actually drive resistance in CRC by only using an…
Cafer BAŞ @brtmnbs
@BrendonStilesMD T3 : combination therapies ie parp inhibitors and IO increases the success in ovarian cancers #lcsm
Brendon Stiles @BrendonStilesMD
@marklewismd You know what they say about rules. And cancer. Break 'em. #lcsm
#LCSM Chat @lcsmchat
RT @n8pennell: @BrendonStilesMD BRAF patient seem to be the one mutant lung cancer population that has a similar response rate to non-mutan…
Nathan A. Pennell MD, PhD @n8pennell
Gotta go, was fun! #lcsm
Janet Freeman-Daily @JFreemanDaily
@n8pennell Thanks for joining us! #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: We don't know. #lungcancer patients who have activating mutations usually don't respond to first-line immunotherapy even…
Brendon Stiles @BrendonStilesMD
@n8pennell Thanks for joining. You are the man. #lcsm
#LCSM Chat @lcsmchat
RT @brtmnbs: @BrendonStilesMD T3 : combination therapies ie parp inhibitors and IO increases the success in ovarian cancers #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @marklewismd You know what they say about rules. And cancer. Break 'em. #lcsm
Alex Spira, M.D. @AlexSpiraMDPhD
RT @ivybelkins: As a stage IV lung cancer patient, I’ve been on targeted therapy for almost 5 years and it’s certainly been a game-changer…
Brendon Stiles @BrendonStilesMD
Fun stuff coming up. Earlier stage! #lcsm
Janet Freeman-Daily @JFreemanDaily
It's been a while since #LCSM Chat was so busy that I couldn't keep up! Seems immunotherapy brings everyone out of the woodwork.
Brendon Stiles @BrendonStilesMD
T4. Is there a role for immunotherapy in patients with stage I-III lung cancer? #lcsm
Matthew Katz, MD @subatomicdoc
@peggyddennis @BrendonStilesMD That's great! @BrendonStilesMD I don't know that there's been as much buzz on RT+anti-angiogenic therapy - though there is a published study looking at it https://t.co/wfvxSbqMWP #lcsm #radonc
Brendon Stiles @BrendonStilesMD
@JFreemanDaily Busy and high yield! #lcsm
MD Anderson Cancer Center @MDAndersonNews
A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: https://t.co/0wSgAgIsv8 #CancerMoonshot #lcsm #endcancer https://t.co/eQtUcjc7EU
Brendon Stiles @BrendonStilesMD
T4. Yes!!! Should be considered as standard for IIIB and unresectable IIIA. #lcsm
#LCSM Chat @lcsmchat
RT @subatomicdoc: @peggyddennis @BrendonStilesMD That's great! @BrendonStilesMD I don't know that there's been as much buzz on RT+anti-angi…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: It's been a while since #LCSM Chat was so busy that I couldn't keep up! Seems immunotherapy brings everyone out of the…
Brendon Stiles @BrendonStilesMD
T4. This is based on groundbreaking PACIFIC trial from @astrazeneca https://t.co/xncbz1YCzN #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Is there a role for immunotherapy in patients with stage I-III lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Yes!!! Should be considered as standard for IIIB and unresectable IIIA. #lcsm
Liz Highleyman @LizCancerHealth
Is there something about the mutation itself that makes tumors less responsive to CPIs, or "colder"? #lcsm https://t.co/CDW3uKAq7G
H. Jack West, MD @JackWestMD
@peggyddennis @BrendonStilesMD There is some scant but provocative data that pts may respond better to chemo after previously receiving immunotherapy. I've seen some vy good responses to docetaxel +/- ramucirumab after IO in some of my clinic pts...better than I'd have expected. More to learn about this. #LCSM
Vamsi Velcheti, MD @VamsiVelcheti
@BrendonStilesMD @peggyddennis @ASCO @JCO_ASCO this is still work in progress- some of the irAEs like cardiac and rheumatologic irAEs are underreported in trials- need to be vigilant while using IO agents Need to develop guidelines on how to monitor patients especially ones with pre-existing risk factors #LCSM
Janet Freeman-Daily @JFreemanDaily
@SMImmunology @SchulichMedDent Glad you joined us! Feel free to chime in. Be sure to include #LCSM in all your tweets.
Brendon Stiles @BrendonStilesMD
T4. Here are the progression free survival curves – favoring patients with Imfinzi (durvalumab). #lcsm https://t.co/vyu8guSTnx
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. This is based on groundbreaking PACIFIC trial from @astrazeneca https://t.co/xncbz1YCzN #lcsm
#LCSM Chat @lcsmchat
RT @LizCancerHealth: Is there something about the mutation itself that makes tumors less responsive to CPIs, or "colder"? #lcsm https://t.c…
Brendon Stiles @BrendonStilesMD
T4. Almost a 50% reduction in disease progression or death with immunotherapy. #lcsm
Michele @rants_by_egg
Immunotherapy is keeping out of the woodwork, literally @JFreemanDaily #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: @peggyddennis @BrendonStilesMD There is some scant but provocative data that pts may respond better to chemo after previous…
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @BrendonStilesMD @peggyddennis @ASCO @JCO_ASCO this is still work in progress- some of the irAEs like cardiac and rheumat…
UC Davis Cancer Cent @UCD_Cancer
Important lung cancer news in @JAMAOnc today with a perspective from our renowned expert @drgandara. #lcsm https://t.co/mgvlNcMsu0
Brendon Stiles @BrendonStilesMD
T4. It is remarkable to me how many groups benefited – even those with low PD-L1 before chemoRT. #lcsm https://t.co/nRA5PMFS6p
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Here are the progression free survival curves – favoring patients with Imfinzi (durvalumab). #lcsm https://t.co/v…
Brendon Stiles @BrendonStilesMD
@JackWestMD @peggyddennis Interesting stuff. #lcsm
Enlightening Results @GraceCordovano
RT @BrendonStilesMD: T1. Side effects are generally less than with chemotherapy, but are unique and include many “itis” problems. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Almost a 50% reduction in disease progression or death with immunotherapy. #lcsm
Janet Freeman-Daily @JFreemanDaily
T4: Some immunotherapy trials are available for early stage #lungcancers. #lcsm
Norman Eng @NoRmiE55
RT @BrendonStilesMD: T4. Almost a 50% reduction in disease progression or death with immunotherapy. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. It is remarkable to me how many groups benefited – even those with low PD-L1 before chemoRT. #lcsm https://t.co/n…
Brendon Stiles @BrendonStilesMD
T4. Immunotherapy now moving into “neoadjuvant” space – treatment before surgery. #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@brtmnbs @lcsmchat @JackWestMD High PDL1 doesn’t always mean the tumor 💡 are ON... PDL1 can be high just because of the mutation and not because of immune cell infiltration #LCSM
Gia Sonata @RedGia
RT @JFreemanDaily: T4: Some immunotherapy trials are available for early stage #lungcancers. #lcsm
Denise Cutlip @dennycee
If it prohibits progression yes @BrendonStilesMD: T4. there a role for immunotherapy in patients with stage I-III lung cancer? #lcsm #lcsm
Enlightening Results @GraceCordovano
RT @BrendonStilesMD: T4. It is remarkable to me how many groups benefited – even those with low PD-L1 before chemoRT. #lcsm https://t.co/n…
Brendon Stiles @BrendonStilesMD
T4. After just 2 doses of Nivolumab (@bmsnews), 45% of tumors had major response! https://t.co/yDjGna2sOT #lcsm
Matthew Katz, MD @subatomicdoc
@BrendonStilesMD T4. Don't patients remain on the drug for a year? So is durvalumab oncostatic or synergistic? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T4: Some immunotherapy trials are available for early stage #lungcancers. #lcsm
Dr. David Tom Cooke @DavidCookeMD
We will find out with neoadjuvant clinical trials. Also adjuvant arm of ALCHEMIST #LCSM https://t.co/0PXkyNpVG0
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Immunotherapy now moving into “neoadjuvant” space – treatment before surgery. #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @brtmnbs @lcsmchat @JackWestMD High PDL1 doesn’t always mean the tumor 💡 are ON... PDL1 can be high just because of the m…
#LCSM Chat @lcsmchat
RT @dennycee: If it prohibits progression yes @BrendonStilesMD: T4. there a role for immunotherapy in patients with stage I-III lung cancer…
Brendon Stiles @BrendonStilesMD
@subatomicdoc I am thinking both. #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we determine that we weren't supposed to use that word? 😉). But just like in the stage IV setting, it's not for everyone #LCSM https://t.co/FnTVGQV6il
Brendon Stiles @BrendonStilesMD
T4. This strategy may lead to cures! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. After just 2 doses of Nivolumab (@bmsnews), 45% of tumors had major response! https://t.co/yDjGna2sOT #lcsm
KC Dill @kasedill
Fast and furious tonight. Lots of great info!! #lcsm
#LCSM Chat @lcsmchat
RT @subatomicdoc: @BrendonStilesMD T4. Don't patients remain on the drug for a year? So is durvalumab oncostatic or synergistic? #lcsm
Jorge Luis Lopez Esq @lopezgovlaw
RT @MDAndersonNews: A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: https://t.co/0wSgAgIsv8 #Cancer
#LCSM Chat @lcsmchat
RT @DavidCookeMD: We will find out with neoadjuvant clinical trials. Also adjuvant arm of ALCHEMIST #LCSM https://t.co/0PXkyNpVG0
#LCSM Chat @lcsmchat
RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we…
Norman Eng @NoRmiE55
@BrendonStilesMD should you reverse or stop treatment if heading towards the latter? #lcsm
Brendon Stiles @BrendonStilesMD
T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH
Dr. David Tom Cooke @DavidCookeMD
"Game-changer" should be banned from #SoME #LCSM https://t.co/fVIJvWnnaq
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH
Brendon Stiles @BrendonStilesMD
@LeciaSequist As moderator I get to make rules. "Game-changer" totally allowed. #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
#personalized immunotherapy- Need scientifically rationale and innovative #biomarker trials- significant challenges to use IO agents from different pharma #LCSM need more @theNCI and cooperative grp @SWOG @eaonc funding
Lecia Sequist, MD, MPH @LeciaSequist
For me, one of the most interesting things about neoadj IO trials is the disconnect between radiographic shrinkage and tumor cell death pathologically. It reminds us that there is a lot we still don't know when we assess our pts clinically #LCSM https://t.co/Mz3RZPrKlr
Gia Sonata @RedGia
RT @BrendonStilesMD: T4. This strategy may lead to cures! #lcsm
Krishna Soujanya Gunturu MD @kgunturuMD
T1. Cardiotoxicity (CT) data is just emerging and so far there are only data from studies already done or from registry data looking at CT. CT is real and we are seeing more, but not very common #LCSM https://t.co/p1zhUQ5sP8
Brendon Stiles @BrendonStilesMD
T4. At @weillcornell @meyerCancer we have a trial using non-ablative SBRT + Imfinzi prior to surgery that is looking good!!! @astrazeneca #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@BrendonStilesMD W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial design @IASLC @ASCO- getting increasingly harder to interpreting trials with no longer relevant control arms- guess good but complex problem to deal with 😀 #LCSM @lcsmchat
Faces of Lung Cancer @LungCancerFaces
@LeciaSequist I. Love. You. That is all. 😂 #lcsm
Dr. David Tom Cooke @DavidCookeMD
Ok, then I am a "Change-agent". #LCSM
Enlightening Results @GraceCordovano
Saying hello to #lcsm! Exciting discussion, will catch up on the discussion if the troops ever go to bed 😂 #Parenting #WomenInHealthcare
Liz Highleyman @LizCancerHealth
RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we…
Vamsi Velcheti, MD @VamsiVelcheti
Clinical trialists shd proactively engage sponsors to amend protocols to adapt trials by flexible “real-time” control arms?? Really need some level of adaptability..It would be a statistical challenge ‘nightmare’ but need innovation in study design here #LCSM @lcsmchat
Enlightening Results @GraceCordovano
RT @JackWestMD: @peggyddennis @BrendonStilesMD There is some scant but provocative data that pts may respond better to chemo after previous…
Brendon Stiles @BrendonStilesMD
T4. At @weillcornell we have trial using non-ablative SBRT + Imfinzi prior to surgery-looking good!!! @astrazeneca #lcsm
Kathleen Skambis @KathleenSkambis
RT @JFreemanDaily: T4: Some immunotherapy trials are available for early stage #lungcancers. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. This strategy may lead to cures! #lcsm
Kathleen Skambis @KathleenSkambis
RT @BrendonStilesMD: T4. Immunotherapy now moving into “neoadjuvant” space – treatment before surgery. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH
Liz Highleyman @LizCancerHealth
RT @BrendonStilesMD: T4. Lots of ongoing trials. #lcsm Exciting stuff. https://t.co/sGWzvXRnXH
Brendon Stiles @BrendonStilesMD
@VamsiVelchev @IASLC @ASCO @lcsmchat Definitely a critical issue moving forward. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: For me, one of the most interesting things about neoadj IO trials is the disconnect between radiographic shrinkage and tu…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @LeciaSequist As moderator I get to make rules. "Game-changer" totally allowed. #lcsm
Saman Maleki, PhD @SMImmunology
The abscopal effect happens when radiation induces an anti-tumor immune response that can destroy tumor cells outside the field of radiation. Abscopal effect is rare since radiation also induces multiple immune inhibitory mechanisms such as TGFb activation #LCSM
#LCSM Chat @lcsmchat
RT @VamsiVelchev: #personalized immunotherapy- Need scientifically rationale and innovative #biomarker trials- significant challenges to us…
#LCSM Chat @lcsmchat
RT @LeciaSequist: For me, one of the most interesting things about neoadj IO trials is the disconnect between radiographic shrinkage and tu…
Vamsi Velcheti, MD @VamsiVelcheti
Also it is critical to relaxing inclusion/exclusion criteria to reflect more “real world” demographics and also will help speed up patient recruitment #LCSM
#LCSM Chat @lcsmchat
RT @krishna_gunturu: T1. Cardiotoxicity (CT) data is just emerging and so far there are only data from studies already done or from registr…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. At @weillcornell @meyerCancer we have a trial using non-ablative SBRT + Imfinzi prior to surgery that is looking…
Janet Freeman-Daily @JFreemanDaily
RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we…
Brendon Stiles @BrendonStilesMD
Still lots of experts here as we move to T5. #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @BrendonStilesMD W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial des…
Dr. David Tom Cooke @DavidCookeMD
Do you have examples of #clincialtrials that have done this? #LCSM https://t.co/CRgpAWjmlY
Brendon Stiles @BrendonStilesMD
T5.  What else do patients want to know about immunotherapy? #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: Clinical trialists shd proactively engage sponsors to amend protocols to adapt trials by flexible “real-time” control arm…
Vamsi Velcheti, MD @VamsiVelcheti
#LCSM @LungMAP @DrRoyHerbstYale @SWOG is a great example of innovative trial design w/multiple arms- indications and combinations w/ possibility to registration #precisionmedicine #innovation #Immunotherapy
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. At @weillcornell we have trial using non-ablative SBRT + Imfinzi prior to surgery-looking good!!! @astrazeneca #…
#LCSM Chat @lcsmchat
RT @SMImmunology: The abscopal effect happens when radiation induces an anti-tumor immune response that can destroy tumor cells outside the…
#LCSM Chat @lcsmchat
RT @VamsiVelchev: Also it is critical to relaxing inclusion/exclusion criteria to reflect more “real world” demographics and also will help…
Brendon Stiles @BrendonStilesMD
@GraceCordovano Glad you popped in! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5.  What else do patients want to know about immunotherapy? #lcsm
Liz Highleyman @LizCancerHealth
RT @VamsiVelchev: @BrendonStilesMD W/ Rapid #IO drug approvals in lung cancer w/ shifting Rx landscape we have challenges in clin trial des…
#LCSM Chat @lcsmchat
RT @VamsiVelchev: #LCSM @LungMAP @DrRoyHerbstYale @SWOG is a great example of innovative trial design w/multiple arms- indications and comb…
Brendon Stiles @BrendonStilesMD
T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.co/BoxM9hMFft #lcsm
Miami Gives @MiamiGives
RT @MDAndersonNews: A professional #drummer got back in the groove after #lungcancer thanks to @MDAProtons: https://t.co/0wSgAgIsv8 #Cancer
Michele @rants_by_egg
T5 How long will it last? #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
@VamsiVelchev @lcsmchat this sounds like it could be a statistical nightmare, but I agree - almost all trials these days have an "obsolete" comparison arm by the time they read out. Thoughts @SuzDahlberg ? #LCSM
Brendon Stiles @BrendonStilesMD
T5. Still need to define better markers or response. #lcsm
Janet Freeman-Daily @JFreemanDaily
Yes, I have metastatic oncogene-driven #lungcancer, but now we have targeted therapy so I can live with cancer as a chronic illness (5 years and counting). #LCSM https://t.co/pkaHCLrPi7
Krishna Soujanya Gunturu MD @kgunturuMD
T4. It would be interesting to see what would be relevant endpoints for neoadjuvang and how the tumor microenvironment looks like after new adjuvant therapy #lcsm https://t.co/g8jXC3Y7yI
Dr. David Tom Cooke @DavidCookeMD
The billion dollar question, #LCSM https://t.co/RDqVVp4veq
Peggy Dennis @peggyddennis
@BrendonStilesMD T5 - Will it work on MY cancer. That's what we all want to know. Confusing data just in the past 2 years. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.…
#LCSM Chat @lcsmchat
RT @LeciaSequist: @VamsiVelchev @lcsmchat this sounds like it could be a statistical nightmare, but I agree - almost all trials these days…
Andy Dillon @lepointvierge
RT @LeciaSequist: I hear this often from multiple fronts and don't understand it. Just because targeted rx doesn't CURE cancer does not mea…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Still need to define better markers or response. #lcsm
Brendon Stiles @BrendonStilesMD
@rants_by_egg Great question. New article in @JCO_ASCO showing 5 year survival 16%. Hopefully, we can do better. #lcsm
colleen ziegler @ZieglerColleen
RT @peggyddennis: @BrendonStilesMD T5 - Will it work on MY cancer. That's what we all want to know. Confusing data just in the past 2 years…
Dr. David Tom Cooke @DavidCookeMD
A5 How long should I take the drug? #LCSM
Gia Sonata @RedGia
@BrendonStilesMD #LCSM A5 I would like the manufacturers to open their post-treatment database to patients. When I called (BMS) I was told they are only tracking SEs for "current pts", not those who have stopped trmt. Huge missed opportunity IMO. This was abt 8 months ago.
#LCSM Chat @lcsmchat
RT @krishna_gunturu: T4. It would be interesting to see what would be relevant endpoints for neoadjuvang and how the tumor microenvironment…
#LCSM Chat @lcsmchat
RT @DavidCookeMD: The billion dollar question, #LCSM https://t.co/RDqVVp4veq
Brendon Stiles @BrendonStilesMD
@peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm
Lee @TheNJIvoryGirl
RT @BrendonStilesMD: Here are some trials. #lcsm https://t.co/IKe92tp5gX
#LCSM Chat @lcsmchat
RT @peggyddennis: @BrendonStilesMD T5 - Will it work on MY cancer. That's what we all want to know. Confusing data just in the past 2 years…
Lee @TheNJIvoryGirl
RT @dennycee: Excellent question RT @peggyddennis: T3 What's most important...Activating mutations or TMB in IO therapy? #LCSM
Lee @TheNJIvoryGirl
RT @BrendonStilesMD: T3:   Is there a role for immunotherapy in patients with activating mutations (EGFR, ALK, ROS1)? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @rants_by_egg Great question. New article in @JCO_ASCO showing 5 year survival 16%. Hopefully, we can do better. #lcsm
Paula Ashton @paulalv
RT @JFreemanDaily: Yes, I have metastatic oncogene-driven #lungcancer, but now we have targeted therapy so I can live with cancer as a chro…
Lee @TheNJIvoryGirl
RT @n8pennell: T2: yes we do have to remember CPIs a great breakthrough but don’t work for everyone. Should not automatically use them in v…
Lee @TheNJIvoryGirl
RT @JFreemanDaily: T1: Note there is more than one type of immunotherapy. For #lungcancer patients, all approved I/O drugs are "checkpoint…
#LCSM Chat @lcsmchat
RT @RedGia: @BrendonStilesMD #LCSM A5 I would like the manufacturers to open their post-treatment database to patients. When I called (BM…
Brendon Stiles @BrendonStilesMD
@peggyddennis But difficult even for doctors to know. Still much to learn. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm
H. Jack West, MD @JackWestMD
Sorry folks, got pulled away...I need to cut out, but great to participate on topic so rapidly changing and giving patients so many new options that are changing what we see as possible for lung cancer & many other cancers. #LCSM
Dr. David Tom Cooke @DavidCookeMD
RT @JackWestMD: Sorry folks, got pulled away...I need to cut out, but great to participate on topic so rapidly changing and giving patients…
Brendon Stiles @BrendonStilesMD
@RedGia That is a great point and something we can push for. #lcsm
Janet Freeman-Daily @JFreemanDaily
T5: If I am treated with an immunotherapy and it stops working, can I take a different immunotherapy later? #lcsm
Norman Eng @NoRmiE55
@BrendonStilesMD #LCSM how to treat side effects.. rn it’s just take some Tylenol or come to the ER for a scan
Saman Maleki, PhD @SMImmunology
Careful design of trials that can combine #radiation with agents that block radiation's immune inhibitory mechanisms have the potential of inducing more abscopal effect. However, this needs to be tailored to the type of cancer and patient #LCSM
Kathleen Skambis @KathleenSkambis
RT @BrendonStilesMD: T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.…
Liz Highleyman @LizCancerHealth
@VamsiVelchev Luckily advocate are on it! #lcsm https://t.co/cw6nGevX0C
Gia Sonata @RedGia
@JFreemanDaily Great question. #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: Sorry folks, got pulled away...I need to cut out, but great to participate on topic so rapidly changing and giving patients…
Denise Cutlip @dennycee
T5: expand reopen Exceptional Responders Program to include pets who’ve done well on IO #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T5: If I am treated with an immunotherapy and it stops working, can I take a different immunotherapy later? #lcsm
Brendon Stiles @BrendonStilesMD
@NoRmiE55 Great question. See new @jco_ASCO article.https://t.co/3wRrRrJu8S #lcsm
#LCSM Chat @lcsmchat
RT @SMImmunology: Careful design of trials that can combine #radiation with agents that block radiation's immune inhibitory mechanisms have…
Lecia Sequist, MD, MPH @LeciaSequist
@peggyddennis @BrendonStilesMD T5: We need better biomarkers to help us all out. On one hand, what is the harm in trying it and seeing? Little harm for most but w/ severe complications and hyperprogression in a minority, there could be harm. Clinical judgement is key, but not always accurate of course. #LCSM
#LCSM Chat @lcsmchat
RT @LizCancerHealth: @VamsiVelchev Luckily advocate are on it! #lcsm https://t.co/cw6nGevX0C
#LCSM Chat @lcsmchat
RT @dennycee: T5: expand reopen Exceptional Responders Program to include pets who’ve done well on IO #lcsm
Dee Sparacio @womenofteal
RT @BrendonStilesMD: @peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: @peggyddennis THIS is the most important question. Personalized discussions w/ oncologist are key. #lcsm
Krishna Soujanya Gunturu MD @kgunturuMD
T5. It depends on the severity of the side effect and how well recovery was. I have few patients who we rechallenged after stopping when they recovered and now continuing on immunotherapy. But in some cases it might worsen too #LCSM https://t.co/mVnf5ZfFNV
Enlightening Results @GraceCordovano
RT @JackWestMD: T2) Important to note that recent study featured at #ASCO18 that gave pembro (KEYTRUDA) as initial treatment for pts w/EGFR…
Brendon Stiles @BrendonStilesMD
Was blowing it so much my twitter account got locked! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @NoRmiE55 Great question. See new @jco_ASCO article.https://t.co/3wRrRrJu8S #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: @peggyddennis @BrendonStilesMD T5: We need better biomarkers to help us all out. On one hand, what is the harm in trying…
#LCSM Chat @lcsmchat
RT @krishna_gunturu: T5. It depends on the severity of the side effect and how well recovery was. I have few patients who we rechallenged a…
Lecia Sequist, MD, MPH @LeciaSequist
@JFreemanDaily So many trials to date have excluded anyone with a h/o prior IO, so in reality we know little about this. My experience w/ a 2nd CPI after prior other CPI is not favorable. Combo's hopefully could be more active? #LCSM
KC Dill @kasedill
RT @JFreemanDaily: T5: If I am treated with an immunotherapy and it stops working, can I take a different immunotherapy later? #lcsm
Gia Sonata @RedGia
@BrendonStilesMD Rut-ro! #lcsm
Brendon Stiles @BrendonStilesMD
@JFreemanDaily Wow! You are all asking the tough questions! Exactly why we need to support more research. #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM
#LCSM Chat @lcsmchat
RT @LeciaSequist: @JFreemanDaily So many trials to date have excluded anyone with a h/o prior IO, so in reality we know little about this.…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @JFreemanDaily Wow! You are all asking the tough questions! Exactly why we need to support more research. #lcsm
Brendon Stiles @BrendonStilesMD
RT @VamsiVelchev: this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM
Lecia Sequist, MD, MPH @LeciaSequist
@LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial designs. #LCSM
#LCSM Chat @lcsmchat
RT @VamsiVelchev: this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM
Brendon Stiles @BrendonStilesMD
Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from you. #lcsm
colleen ziegler @ZieglerColleen
RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial design…
Brendon Stiles @BrendonStilesMD
@LeciaSequist @LizCancerHealth @VamsiVelchev Great point. #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial design…
Sara Whitlock @sjwhitlock
@VamsiVelchev I absolutely agree. Because I have history of brain Mets I think that until recently I would have been excluded #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from…
Paula Ashton @paulalv
RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial design…
Brendon Stiles @BrendonStilesMD
Almost time to wind the chat down. This has been an incredible discussion. #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from…
Brendon Stiles @BrendonStilesMD
Please share your closing thoughts! #lcsm
Lecia Sequist, MD, MPH @LeciaSequist
@BrendonStilesMD @RedGia @US_FDA is set up to track this in theory, but it is not a perfect system. #LCSM
Matthew Katz, MD @subatomicdoc
RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial design…
Dee Sparacio @womenofteal
@LeciaSequist @peggyddennis @BrendonStilesMD Maybe we need to study those already in trial that respond quickly and those who have hyperprogression ( and may have to leave the trial ) to see how they differ. #LCSM
Paula Ashton @paulalv
RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from…
Brendon Stiles @BrendonStilesMD
@sjwhitlock @VamsiVelchev Who would ever exclude you?! Have they met you? Impossible. #lcsm
Dr. David Tom Cooke @DavidCookeMD
Another great chat everyone! Thanks @BrendonStilesMD #LCSM
Krishna Soujanya Gunturu MD @kgunturuMD
@JFreemanDaily T5 @JFreemanDaily we don’t have much data about treating with another IO after progression. May be adding chemo to IO would work. Still need answers #lcsm
KC Dill @kasedill
RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from…
Dee Sparacio @womenofteal
RT @krishna_gunturu: T5. It depends on the severity of the side effect and how well recovery was. I have few patients who we rechallenged a…
Brendon Stiles @BrendonStilesMD
Thanks to all of the #lcsm community who joined. And BIG thanks to all of our guests tonight. Incredible turnout! #lcsm
#LCSM Chat @lcsmchat
RT @sjwhitlock: @VamsiVelchev I absolutely agree. Because I have history of brain Mets I think that until recently I would have been exclud…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Almost time to wind the chat down. This has been an incredible discussion. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please share your closing thoughts! #lcsm
Janet Freeman-Daily @JFreemanDaily
NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not visible in https://t.co/A2M7gY7Hvl!
Paula Ashton @paulalv
RT @womenofteal: @LeciaSequist @peggyddennis @BrendonStilesMD Maybe we need to study those already in trial that respond quickly and those…
Liz Highleyman @LizCancerHealth
@LeciaSequist @VamsiVelchev No indeed! #righttotry is unlikely to improve access much, but expanded trial criteria could #lcsm
colleen ziegler @ZieglerColleen
Thank you all, lots of good information shared tonight #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @JFreemanDaily: NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not v…
Brendon Stiles @BrendonStilesMD
@womenofteal @LeciaSequist @peggyddennis Yes. Definitely need to figure out what "hyperprogession" is and who it occurs in. #lcsm
Vamsi Velcheti, MD @VamsiVelcheti
@LeciaSequist @LizCancerHealth good point! this is such a complicated topic... didn’t expect to be discussing this with patients so often... may be a good topic for the next #LCSM chat @BrendonStilesMD
Dee Sparacio @womenofteal
RT @VamsiVelchev: this is perhaps going to be more meaningful (real) progress compared to “right to try” #LCSM https://t.co/jLwux4Y4nM
Denise Cutlip @dennycee
Closing thought: This is an exciting time to be a patient and an advocate. Unprecedented. #lcsm
Janet Freeman-Daily @JFreemanDaily
Thanks to @BrendonStilesMD for a great blog and engagement as tonight's #LCSM Chat moderator! See you all in the next chat!
Faces of Lung Cancer @LungCancerFaces
Thank you @BrendonStilesMD for your thoughtful blog post, amazing preparation and skillful moderation. #lcsm
Paula Ashton @paulalv
#LCSM great discussion tonight. Thank you @BrendonStilesMD for moderating
Peggy Dennis @peggyddennis
@dennycee My sentiments exactly! #lcsm
Brendon Stiles @BrendonStilesMD
What a seriously incredible group - patients, med onc, path, rad onc, surgeons, scientists, pharm. So meaningful. #lcsm
#LCSM Chat @lcsmchat
RT @LeciaSequist: @BrendonStilesMD @RedGia @US_FDA is set up to track this in theory, but it is not a perfect system. #LCSM
#LCSM Chat @lcsmchat
RT @womenofteal: @LeciaSequist @peggyddennis @BrendonStilesMD Maybe we need to study those already in trial that respond quickly and those…
#LCSM Chat @lcsmchat
RT @krishna_gunturu: @JFreemanDaily T5 @JFreemanDaily we don’t have much data about treating with another IO after progression. May be addi…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to all of our guests tonight. Incredible turnout! #l
Paula Ashton @paulalv
RT @dennycee: Closing thought: This is an exciting time to be a patient and an advocate. Unprecedented. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not v…
Kathleen Skambis @KathleenSkambis
Great, great #LCSM chat. Thank you all so much for sharing and doing so with great humor and compassion.
#LCSM Chat @lcsmchat
RT @LizCancerHealth: @LeciaSequist @VamsiVelchev No indeed! #righttotry is unlikely to improve access much, but expanded trial criteria cou…
Sherry Reynolds 🌟 @Cascadia
RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @womenofteal @LeciaSequist @peggyddennis Yes. Definitely need to figure out what "hyperprogession" is and who it occu…
Krishna Soujanya Gunturu MD @kgunturuMD
Thank you all for a great chat tonight #lcsm
Brendon Stiles @BrendonStilesMD
@LungCancerFaces Just got lucky that so many talented people showed up! #lcsm
#LCSM Chat @lcsmchat
RT @VamsiVelchev: @LeciaSequist @LizCancerHealth good point! this is such a complicated topic... didn’t expect to be discussing this with p…
#LCSM Chat @lcsmchat
RT @dennycee: Closing thought: This is an exciting time to be a patient and an advocate. Unprecedented. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Thanks to @BrendonStilesMD for a great blog and engagement as tonight's #LCSM Chat moderator! See you all in the next ch…
#LCSM Chat @lcsmchat
RT @LungCancerFaces: Thank you @BrendonStilesMD for your thoughtful blog post, amazing preparation and skillful moderation. #lcsm
Brendon Stiles @BrendonStilesMD
RT @JFreemanDaily: NOTE: check out the actual #LCSM Twitter feed or tonight's transcript to see longer (>140) tweets--some good stuff not v…
Anita Figueras @scifiknitter
RT @JFreemanDaily: Thanks to @BrendonStilesMD for a great blog and engagement as tonight's #LCSM Chat moderator! See you all in the next ch…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: What a seriously incredible group - patients, med onc, path, rad onc, surgeons, scientists, pharm. So meaningful. #lc
#LCSM Chat @lcsmchat
RT @KathleenSkambis: Great, great #LCSM chat. Thank you all so much for sharing and doing so with great humor and compassion.
Brendon Stiles @BrendonStilesMD
@krishna_gunturu Thanks for joining! #lcsm
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: What a seriously incredible group - patients, med onc, path, rad onc, surgeons, scientists, pharm. So meaningful. #lc
Brendon Stiles @BrendonStilesMD
@sjwhitlock @VamsiVelchev Love right back at you! #lcsm
Janet Freeman-Daily @JFreemanDaily
Thanks everyone for a great chat! #lcsm
Matthew Katz, MD @subatomicdoc
@LungCancerFaces @BrendonStilesMD Yes, thanks Brendon! Thanks to everyone who share their thoughts and experience tonight as well #lcsm
Brendon Stiles @BrendonStilesMD
@womenofteal @JFreemanDaily Thanks for joining! #lcsm
Brendon Stiles @BrendonStilesMD
@subatomicdoc @LungCancerFaces Thanks for joining! #lcsm
Gia Sonata @RedGia
@BrendonStilesMD #lcsm Closing thoughts: Very much enjoyed. I look forward to more IO discussions in the future. Night, night all!
Norman Eng @NoRmiE55
RT @BrendonStilesMD: Here is a closing thought. From my Dad's grave stone. Live by this creed. #lcsm https://t.co/V0sqFoVK8E
Brendon Stiles @BrendonStilesMD
@jfowlerpharmd This one was tough to keep up with. Barely managed to get the snarky stuff in! #lcsm
Peggy Dennis @peggyddennis
RT @LungCancerFaces: Thank you @BrendonStilesMD for your thoughtful blog post, amazing preparation and skillful moderation. #lcsm
Brendon Stiles @BrendonStilesMD
@kasedill Thanks for joining! #lcsm
Dr. David Tom Cooke @DavidCookeMD
I suggest that patients and families take the transcript from this #immunotherapy @lcsmchat chat and use it as a study aid! #LCSM
Brendon Stiles @BrendonStilesMD
@RedGia Thanks for participating! #lcsm
Brendon Stiles @BrendonStilesMD
@marklewismd Indeed. Thanks for that. #lcsm
Janet Freeman-Daily @JFreemanDaily
@LeciaSequist Aha! I just figured it out. "CPI" means "checkpoint inhibitor," a specific type of immunotherapy. Now I can go to sleep tonight. ;) #LCSM
Brendon Stiles @BrendonStilesMD
Good night everyone!!! Thanks. Keep working for our lung cancer community. #lcsm
Gia Sonata @RedGia
@BrendonStilesMD Thanks for moderating. Our group does a great job of making it look easy! #lcsm
Jaye @HealthCoachJaye
RT @BrendonStilesMD: Here is a closing thought. From my Dad's grave stone. Live by this creed. #lcsm https://t.co/V0sqFoVK8E
ALKLungCancerBarbie @VirginiaMByrne
#lcsm Thank you all for this informative online gathering.
Gia Sonata @RedGia
@JFreemanDaily There is so much to share! #lcsm
Judith Martin @judithemartin
RT @BrendonStilesMD: Here is a closing thought. From my Dad's grave stone. Live by this creed. #lcsm https://t.co/V0sqFoVK8E
Dennis Deruelle, MD @Drderuelle
RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from…
John @joltdude
RT @LeciaSequist: @LizCancerHealth @VamsiVelchev Do not confuse right to try law with better, innovative, more modern clinical trial design…
Pablo Pérez Castro @pabloperezc
RT @DavidCookeMD: A2 More and more neoadjuvant surgical #immunotherapy #clincialtrials are becoming available. #LCSM
Omalkhaire Alshaikh @alshaikh28
RT @BrendonStilesMD: Here is a closing thought. From my Dad's grave stone. Live by this creed. #lcsm https://t.co/V0sqFoVK8E
Janet Freeman-Daily @JFreemanDaily
Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: https://t.co/2Wm4gnbpWQ
Pablo Pérez Castro @pabloperezc
RT @BrendonStilesMD: T2. For patients with PD-L1 expression >50%, Keytruda monotherapy (@merck) is indicated for both adeno and squamous #…
Matthew Katz, MD @subatomicdoc
RT @JFreemanDaily: Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: https://t.co/2Wm4gnbpWQ
Pablo Pérez Castro @pabloperezc
RT @BrendonStilesMD: T5. Important to remember -“miracle cures” aren’t miracles for everyone. From @marklewismd earlier today. https://t.…
Timothy Craig Allen @TimAllenMDJD
RT @JFreemanDaily: Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: https://t.co/2Wm4gnbpWQ
Gia Sonata @RedGia
RT @JFreemanDaily: Transcript for 14-Jun-2018 #LCSM Chat "#Immunotherapy–the ultimate personalized therapy" is here: https://t.co/2Wm4gnbpWQ
Shikha Jain MD, FACP @ShikhaJainMD
I missed out on the live #lcsm chat tonight! Will have to go through and see what I missed later tonight. I heard it was a good one! @lcsmchat
Joe Baber @JoeBaber1
RT @BrendonStilesMD: Here are different types: #lcsm https://t.co/jnehLpt5uy
Huren Sivaraj @HSivarajMD
RT @LeciaSequist: The PACIFIC trial is the first real advance in stage III NSCLC in my career (15 years). A major game-changer (or did we…
conciergedoc @DrFerdowsi
RT @BrendonStilesMD: Doctors need patients and advocates to constructively share their stories and experiences. That is how we learn from…
#LCSM content from Twitter.